Protagonist Therapeutics, Inc.
PTGX
Kedudukan dalam Saham
#2222
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Harga Saham
$138.22
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$8.94B
Perubahan (1 hari)
0.16%
Perubahan (1 tahun)
88.05%
Negara
US
Perdagangan Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Sejarah harga saham bagi Protagonist Therapeutics, Inc. (PTGX)
Harga penutupan tertinggi: $138.58 pada 2026-10-01
Harga penutupan terendah: $11.34 pada 2016-08-01
Harga penutupan terendah: $11.34 pada 2016-08-01
Sejarah harga saham Protagonist Therapeutics, Inc. dari 2016 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 21.74% |
| 2025 | 119.26% |
| 2024 | 92.93% |
| 2023 | 131.51% |
| 2022 | -72.05% |
| 2021 | 46.48% |
| 2020 | 203.82% |
| 2019 | 9.00% |
| 2018 | -65.01% |
| 2017 | -15.57% |
| 2016 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $761.12 | 8.18% |
CH
|
